A Wockhardt facility sanctioned by Indian authorities last week has resumed production of three fixed dose combination (FDC) drugs.
The facility in the Himachal Pradesh region of India was banned from manufacturing, selling or distributing FDCs of Dicyclomine Hydrochloride IP 10mg, Tramadol Hydrochloride IP 50mg & Acetamenophen IP 325mg last week by the State Drug Controller , though the company gave no reason for the actions.
However, in a filing to the Bombay Stock Exchange yesterday, Wockhardt has announced the suspension has now been revoked and “accordingly the Company will continue to manufacture, sell and distribute.”
No further information was given and this publication was unable to obtain further comment from Wockhardt.
In other news, the firm has hit back at a press article claiming generics drugmaker Mylan was in talks to acquire Wockhardt’s domestic business, whilst Big Pharma firm Pfizer was also looking to buy some of the firm’s assets.
“We deny the media reports and would like to inform that the Company has been informing the exchange about events, information etc. including price sensitive information in accordance with regulatory requirements,” Wockhardt said in a filing.